Zimberelimab + Domvanalimab + FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)

Phase 2Withdrawn

0 views this week 0 watching💤 Quiet

Interest: 21/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Adenocarcinoma Stomach

Conditions

Adenocarcinoma Stomach, Adenocarcinoma Gastroesophageal Junction

Trial Timeline

Feb 1, 2026 → Dec 1, 2029

NCT ID

NCT07283848

About Zimberelimab + Domvanalimab + FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)

Zimberelimab + Domvanalimab + FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel) is a phase 2 stage product being developed by Arcus Biosciences for Adenocarcinoma Stomach. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT07283848. Target conditions include Adenocarcinoma Stomach, Adenocarcinoma Gastroesophageal Junction.

What happened to similar drugs?

1 of 20 similar drugs in Adenocarcinoma Stomach were approved

Approved (1) Terminated (0) Active (19)

✅ApatinibTabletsJiangsu Hengrui MedicineApproved

🔄Ramucirumab + Paclitaxel + PlaceboEli LillyPhase 3

🔄CT-P16 + AvastinCelltrionPhase 3

🔄Bevacizumab + Capecitabine + Cisplatin + Placebo + 5-fluorouracilChugai PharmaceuticalPhase 3

🔄Trastuzumab deruxtecan + Ramucirumab + PaclitaxelDaiichi SankyoPhase 3

🔄zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3

🔄zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07283848	Phase 2	Withdrawn	Feb 1, 2026	Dec 1, 2029	Adenocarcinoma Stomach

Competing Products

20 competing products in Adenocarcinoma Stomach

See all competitors

Product	Company	Stage	Hype Score
CD40 agonist mitazalimab in combination with chemotherapy	Alligator Bioscience AB	Phase 1/2	26
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + Bendamustine	Lonza	Phase 1	18
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359	Perspective Therapeutics	Phase 1/2	33
Zentalis + Gemzar	Zentalis Pharmaceuticals	Phase 2	29
ACR-368 + Gemcitabine	Acrivon Therapeutics	Phase 2	32
Ramucirumab	Eli Lilly	Phase 1/2	32
Ramucirumab + Paclitaxel + Placebo	Eli Lilly	Phase 3	40
BA3182	BioAtla	Phase 1	26
Ramucirumab (IMC-1121B ) + Paclitaxel	Eli Lilly	Phase 1	29
CT-P16 + Avastin	Celltrion	Phase 3	40
Bevacizumab + Capecitabine + Cisplatin + Placebo + 5-fluorouracil	Chugai Pharmaceutical	Phase 3	40
Trastuzumab Deruxtecan	Daiichi Sankyo	Phase 2	35
Trastuzumab deruxtecan + Ramucirumab + Paclitaxel	Daiichi Sankyo	Phase 3	44
Trastuzumab Deruxtecan (T-DXd) monotherapy + T-DXd, Durvalumab and Capecitabine Combination	Daiichi Sankyo	Phase 2	42
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	35
DS-8201a	Daiichi Sankyo	Phase 1	29
Trastuzumab deruxtecan + 5FU/LV + Trastuzumab deruxtecan + FLO	Daiichi Sankyo	Phase 1/2	39
Enzalutamide	Astellas Pharma	Phase 2	35
zolbetuximab	Astellas Pharma	Pre-clinical	30
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracil	Astellas Pharma	Phase 3	44